Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 31%
Buy 20%
Hold 43%
Sell 6%
Strong Sell 0%

Bulls say

Incyte demonstrated a strong performance in the fourth quarter, driven primarily by robust demand for its leading drug, Jakafi, which generated $773 million in revenue, surpassing expectations and reflecting minimal impact from competition. The company also reported promising clinical results for its dermatology product, Opzelura, indicating significant improvements for patients with atopic dermatitis, further enhancing its revenue potential. Additionally, the positive commercial trajectory of Incyte's legacy products, alongside a promising pipeline featuring best-in-class assets like povorcitinib, suggests a sustained growth outlook, particularly as the company navigates the upcoming Jakafi patent cliff in 2028.

Bears say

Incyte's negative outlook is influenced by eroding pricing power for its lead drug, Jakafi, alongside anticipated slowing usage. The company faces significant risks, including performance issues with its earlier-stage pipeline, competitive pressures, and various regulatory uncertainties that could hinder Jakafi's lifecycle. Additionally, a lack of compelling clinical data for its products and emerging competitors may adversely affect future sales growth and overall financial performance.

Incyte (INCY) has been analyzed by 35 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 20% recommend Buy, 43% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 35 analysts, Incyte (INCY) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.